Meeting
2013 Gastrointestinal Cancers Symposium
Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.
Authors
Johanna Bendell
Sarah Cannon Research Institute/Tennessee Oncology
Johanna Bendell , Lowell Hart , Shubham Pant , Jeffrey Infante , Suzanne Jones , Adil Mohyuddin , Patrick Murphy , Jeffrey Patton , William Penley , Dana Thompson , Howard Burris III
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01226732
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr475)
DOI
10.1200/jco.2013.31.4_suppl.475
Abstract #
475
Poster Bd #
C31
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.
First Author: Shubham Pant
Poster
2017 ASCO Annual Meeting
First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.
First Author: Noriko Yanagitani
Poster
2013 ASCO Annual Meeting
Phase I study of c-Met inhibitor ARQ197 in combination with FOLFOX for the treatment of patients with advanced solid tumors.
First Author: Suzanne Fields Jones
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska